Market Overview The U.S. subcutaneous immunoglobulin (SCIG) sector is experiencing rapid growth due to increasing prevalence of primary immunodeficiency diseases (PIDs), rising adoption of self-administered therapies, and advancements in biologics. Valued at USD 3.86 billion in 2024, the sector is projected to grow at a CAGR of 9.4% from 2025 to 2034, reaching USD 9.46...